India Glycols Q2 FY27: consolidated PAT ₹23.7 Cr as chemicals-only entity post-demerger
PAT -63.58% YoY · revenue -84.97% · margins compressing
₹362.42 Cr
-84.97% YoY
₹23.69 Cr
-63.58% YoY
6.53%
+3.8pp YoY
₹3.53
India Glycols Limited (consolidated, primary) reported Q2 FY27 revenue from operations of ₹362.42 Cr and net profit of ₹23.69 Cr (basic/diluted EPS ₹3.53) for the quarter ended 30 September 2026 — its first quarter reporting solely as the continuing Bio-based Specialties and Performance Chemicals business. Under the NCLT-approved Scheme of Arrangement (appointed date 1 April 2026, effective 1 September 2026), the Spirits and Biofuel Undertaking was demerged into IGL Spirits Limited and the Biopharma Undertaking into Ennature Bio Pharma Limited, both of which received NSE/BSE listing and trading approval on 2 November 2026. Because the year-ago comparative (₹2,412.40 Cr revenue, ₹65.06 Cr PAT) still carries the now-demerged businesses, the reported YoY declines of roughly -85% in revenue and -64% in PAT are an artefact of the restructuring, not an operating collapse, and should not be read as this quarter's performance verdict.
Q2 FY-2027 vs prior quarters
The cleaner read is sequential: Q1 FY27 (30 June 2026) was itself restated for the same demerger, so like-for-like, revenue was roughly flat quarter-on-quarter (₹357.45 Cr → ₹362.42 Cr, +1.4%) while PAT fell 27.3% (₹32.59 Cr → ₹23.69 Cr) as consolidated net margin compressed to ~6.5% from ~9.1% and EBITDA margin slipped to ~10.8% from ~11.3%. Standalone PAT of ₹11.24 Cr is roughly half the consolidated figure — the gap is the ₹12.64 Cr JV share from Clariant IGL Specialty Chemicals, itself down 39% QoQ from ₹20.60 Cr, so the JV's own softness is a swing factor separate from the standalone chemicals business's performance. Management's only surviving numeric aspiration for this residual entity — ₹150 Cr FY27 EBITDA for the Chemicals business, from the August 2026 concall — looks roughly on track: standalone H1 FY27 EBITDA of ₹79.55 Cr annualises to about ₹159 Cr. No sell-side consensus for this post-demerger, chemicals-only entity's Q2 print turned up in a search (only the pre-demerger Q1 FY27 Arihant estimate and the Nov 18 earnings-call announcement were found), so vs-street is unknown rather than a beat or miss; management gives no formal quarterly guidance beyond the multi-year aspirations carried over from the pre-demerger concall.
The stock went into the print at ₹311.3, down 11% over the past month of trading.
For context: PAT has now risen for 3 consecutive quarters.
Potable Spirits FY27 EBITDA >₹500 Cr (₹120 Cr delivered Q1). Chemicals aspiration ₹150 Cr FY27, ₹400 Cr in 4-5 yrs. Ennature aspiration ₹130-150 Cr EBITDA in 4-5 yrs. Debt-free FY28 target.
— This quarter: met
Among the quarter's developments: Alok Singhal was re-appointed Executive Director for three years (13 November 2026), and the company absorbed a ₹6.22 lakh GST e-way bill penalty (10 October 2026) — immaterial to the P&L. Consolidated debt fell to ₹825.97 Cr (30 September 2026) from ₹1,578.47 Cr (31 March 2026), but the drop is mostly the Spirits business's debt leaving the balance sheet via the demerger rather than organic deleveraging, so it cannot yet be read against management's FY28 debt-free target for this residual entity. Going into Q3, the markers are whether the chemicals EBITDA run-rate holds near the ₹150 Cr annual aspiration, whether the JV's profit contribution recovers from this quarter's dip, and how the much smaller standalone balance sheet trends now that Spirits and Biopharma report separately.
W1
Chemicals EBITDA run-rate vs management's ₹150 Cr FY27 aspiration — H1 standalone EBITDA at ₹79.55 Cr, needs roughly ₹70-80 Cr in H2 to hold pace
W2
Clariant IGL JV profit contribution — fell to ₹12.64 Cr this quarter from ₹20.60 Cr last quarter; watch for recovery or further softness
W3
Debt trajectory toward management's FY28 debt-free target now that the balance sheet is ~₹826 Cr of consolidated borrowings post-demerger
Informational and educational content only. Not investment advice.